Avanos Medical Inc 2025年度报告
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nformation Concerning Forward-Looking StatementsThis Annual Report on Form 10-K (this “Form 10-K”) and other materials we have filed or furnished or will file or furnish with the SEC (as well as information included in our oral or other written statements) contain, or will contain, certain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding business strategies,market potential, future financial performance and other matters. Forward-looking statements may appear throughout this Form10-K, including without limitation, in the following sections: Item 1 “Business;” Item 1A “Risk Factors;’ and Item 7“Manag
